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Objectives: Switzerland’s regulation of prices for reimbursed drugs is based on 
referencing across countries and within the therapeutic class for products with 
comparators. The SwissHTA initiative involving all key stakeholders in the health 
care systems (sickness funds, industry, physicians, academia, Kantons) has pub-
lished consensus papers for new benefit criteria and measurements. MethOds: 
A comparison was executed comparing the new proposed criteria against benefit 
assessments in HTA systems in Germany and the UK. Results: In terms of clinical 
benefit assessment the suggestion by SwissHTA follows accepted evidence-based 
methods. In comparison to Germany the Swiss approach suggests a pragmatic 
application by applying disease specific standards. This disease focus allows also 
accepting different levels of evidence given the characteristics of the disease. This 
pragmatic approach allows Swiss decision-makers accepting lower evidence levels 
at the time of launch (e.g. in case of comparison with non-Swiss standard-of-care) 
coupled with a post-reimbursement commitment. The Swiss method looks simi-
lar to the medical benefit application by NICE. In terms of health economic (HE) 
evaluations SwissHTA suggests focusing on technical efficiency instead of QALY 
comparisons across the whole system as in the UK. Such an approach avoids the 
application of arbitrarily defined cost-effectiveness thresholds. In Germany the HE 
focus is solely based on cost comparisons. In terms of decision-making in Germany 
the focus is based on an assessment of the available evidence against a theoreti-
cal maximum standard of evidence. In the UK coverage decisions are based on 
cost-effectiveness assessments allowing for context-specific adjustments. In the 
SwissHTA recommendation a multi-criteria decision-making should be applied 
with an equal focus on all key aspects (e.g. clinical benefit, public relevance, social 
preferences, etc.). cOnclusiOns: In comparison to HTA systems in Germany and 
UK the SwissHTA recommendations seems to be more pragmatic and would follow 
a broader multi-criteria decision making approach.
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Objectives: FDA has long recognized that dramatic increase in adverse event 
reports due to medical devices and recalls may reflect quality flaws. While some 
of this increase can be explicated by FDA’s greater outreach emphasizing reporting 
requirements, failures in product design and manufacturing process cause more 
than half of all product recalls. Therefore, FDA’s concern regarding low quality prod-
ucts remains. In the EU, medical device pre-market quality is assured by CE mark 
authorization. This regulation is the prerequisite for market registration also for 
Turkey. However, due to heterogeneity and complexity of devices, manufacturers, 
imported devices and multiple use environments, there is strong need for post-
market quality assurance. MethOds: This study investigates whether post-market 
quality assurance (measured by less adverse events/better health outcomes) can be 
applied through local reimbursement policies. First, it is investigated whether there 
are reimbursement rules in Europe acting as post-market quality assurance. Then, 
a comparison is made with Turkey’s existing reimbursement scheme. Results: 
Our comparative analysis reveals only Belgium and France implement quality or 
brand based reimbursement rules. In Turkey, there is no quality based reimburse-
ment scheme; however current reimbursement application guideline requirements 
may act as a gate keeper for lower quality products. Our Results show in addition 
to pre-market regulations, post-market quality can be assured by local reimburse-
ment authorities. cOnclusiOns: There are several opportunities to improve 
quality assurance and reduce risk across medical device industry; i.e. enhancing 
visibility of comparative quality to harness market forces and increasing the col-
laboration between stakeholders. From health policy perspective, implementation 
of new value based reimbursement models require providers to prove that they’re 
meeting quality standards and benefitting patients while cutting costs. Therefore, 
while value based payment contracts are still in their infancy in Europe and Turkey, 
they will have a direct impact on the assurance of continued medical device quality.
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Objectives: In Germany, Scotland and the Netherlands, the manufacturer’s 
submission is assessed by the HTA bodies; G-BA, SMC and NZi. In Germany, the 
submitted evidence is used to assess the drug’s additional benefit, followed by 
price-rebate negotiations with the GKV-Spitzenverband. In Scotland and the 
Netherlands, the submitted evidence is evaluated for reimbursement decision. 
This study aims to compare factors that influence the reimbursement recom-
mendation by SMC and NZi, the additional benefit by G-BA and the rebate by 
GKV-Spitzenverband. MethOds: Three databases were created consisting of 
463 SMC applications, 262 NZi evaluations and 68 G-BA decisions. Logistic regres-
sion analyses were conducted to assess the impact of the submitted evidence 
on the recommendation by SMC and NZi and the effect of variables on the addi-
tional therapeutic benefit by G-BA. The impact of variables on the rebate was 
examined through linear regression analysis. Results: In Scotland, 57% of the 
applications received positive recommendation and the NZi recommended 83% of 
the submissions. In Germany, 60.3% of the products demonstrated an additional 
benefit. In Scotland, the multivariate analyses showed that the performance of a 
cost-minimization analysis and beneficial cost-effectiveness outcomes were the 
strongest positive predictors of the recommendation. In the Netherlands, univari-
ate analyses showed that the decision was significantly affected by whether the 
product under assessment was a life-saving intervention and the inclusion of 
(positive) economic evidence. In Germany, univariate analyses demonstrated that 
the therapeutic indication and the overall survival benefit, along with improved 
morbidity and adverse events meaningfully influenced the benefit assessment. 
Analysis showed that the rebate was significantly reduced by 13% for products 
that demonstrated additional benefit. cOnclusiOns: Even though reimburse-
ment submission requirements of Scotland and the Netherlands look similar, 
SMC weights the cost-effectiveness outcomes more, while NZi focuses on the 
variables related to additional clinical benefit; variables that also significantly 
influence G-BA’s decision.
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Objectives: The Pharmaceutical Market Restructuring Act (AMNOG) has brought 
a sustainable change to the reimbursement of new drugs in Germany. The G-BA 
assesses the additional benefit of the drug, compared to an appropriate therapy. 
AMNOG law is perceived to be one of the toughest drug evaluation process in Europe. 
In France the high authority for health (HAS) assesses the level of improvement of 
actual benefit (IAB). The objective of this study was to compare the additional benefit 
score issued under AMNOG law to IAB scores granted by the HAS. MethOds: All 
G-BA’s additional benefit scores until June 1st 2014 and HAS IAB score were com-
pared. Results: In Germany, a total of 76 completed early benefit assessments. 
From the best available score perspective, the G-BA assessed the additional benefit 
as considerable in 20% of drugs assessed (score 2), as minor in 30% of drugs assessed 
(score 3), as unquantifiable in 8% of drugs assessed (Score 4) and as none in 38% 
of drugs assessed (Score 5). No drug has been granted a major additional benefit 
(score 1) and 4% of drugs were directly allocated to a reference price group. In France, 
the transparency committee granted a major improvement in 0.2% of cases (IAB 
I), an important improvement in 1.3% of cases (IAB II), a moderate improvement 
2.5% of cases (IAB III), a minor improvement in 9,2% of cases (IAB 4) and no clini-
cal improvement in 86.8% of cases (IAB V). cOnclusiOns: This study shows that 
the G-BA assigned an additional benefit (scores from 1 to 4) to more than half of 
drugs whereas the HAS granted an additional benefice rating to less than 14% of 
case. This study suggests that there is a more favourable benefit rating in Germany 
than in France.
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Objectives: Biosimilars have the potential to revolutionise the health care land-
scape by realising cost savings over originator biologics and thus increasing access 
to innovative medicines. The biosimilars marketplace in the UK and Ireland is 
relatively new, however the landscape is rapidly developing. The objective of this 
analysis was to map the HTA status of biosimilars in the UK and Ireland to provide 
insight for stakeholders involved in the assessment of new biosimilars. MethOds: 
The HTA status of all EMA authorised biosimilars was identified by searching the 
websites of all four HTA agencies in the UK and Ireland, namely, NICE, the SMC, the 
AWMSG, and the NCPE. All previously assessed medicines and on-going technology 
appraisals were screened for the inclusion of biosimilars using the non-proprietary 
(common name) and proprietary (brand) names. Results: Sixteen (84%) of the 
nineteen biosimilars submitted to the EMA have been authorised, eleven of which 
(69%) have been considered by HTA agencies. The SMC has approved 100% of the 
biosimilars it has considered (n= 7); the largest positive reimbursement rate amongst 
all HTA agencies considered. The AWMSG has considered the largest number of 
biosimilars (n= 11), of which five, (45%) received a positive reimbursement status. 
Both NICE and the NCPE have approved one biosimilar, however three additional 
biosimilars are currently being considered by NICE. cOnclusiOns: The reim-
bursement status of biosimilars in the UK and Ireland is not consistent across HTA 
agencies. The timing of HTA submissions to different HTA agencies may play an 
important factor in the reimbursement status of biosimilars given that this land-
scape is relatively new and assessment processes vary. Marketing authorisation 
holders for biosimilars may want to consider the strategic importance of submitting 
evidence to each of the HTA agencies in the UK and Ireland, and the impact timing 
may have on the uptake of their biosimilar.
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Objectives: Identifying the right patient population, comparator and endpoints is 
key to increase the likelihood of reimbursement. Manufacturers do not always agree 
with payers’ views on these items. Disagreement may lead to funding rejection. We 
assessed the rate of mismatches between manufacturers and NICE and their impact 
on the final appraisal outcome. MethOds: All manufacturer submissions (MS) 
from January 2011 until June 2014 were reviewed. For these submissions, the initial 
proposed scope, the manufacturer’s comments, and the final scope and appraisal 
outcome were analysed. All changes to the initial scope suggested by the manu-
facturer were recorded and their impact on final outcome investigated. Results: 
In the time period reviewed there were 101 MS of which 7 were suspended and 
not included in our analysis, while comments were not available for another 18. 
Manufacturer comments are published for 76 MS. The manufacturer disagreed on 
≥ 1 section of initial scope in 93% (71/76) of MS. The areas where manufacturers and 
NICE disagreed most commonly are the comparator(s) (43/71; 61%) and population 
(40/71; 56%) to be assessed. The final scope implemented all and some of the manu-
facturer’s comments in 56% (40/71) and 28% (29/71) of submissions, respectively. 
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Rejection was more common for manufacturer’s comments on outcomes (6/8; 75%) 
and comparators (8/13; 61.5%). Rate of final recommendation by NICE was higher 
for those MS where all (29/40; 74%) or certain changes (14/20; 74%) requested by 
the manufacturer were implemented in the final scope than for those where NICE 
rejected all manufacturer requests (7/11; 64%), and similar to overall recommenda-
tion rate (66/91; 73%). cOnclusiOns: These data highlight that the initial scope 
frequently does not meet manufacturer’s expectations. However, manufacturer’s 
suggestions are often incorporated in the final scope. NICE not implementing manu-
facturer’s suggestions to the final scope does not decrease the likelihood of being 
granted funding.
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Objectives: Biosimilars and biobetters are subsequent versions of licensed innova-
tor biotherapeutics. Whereas biosimilars are comparable to the originator product 
in terms of quality, safety and efficacy, biobetters incorporate intentional modifi-
cations to the originator molecular profile with the aim of producing a superior 
product. This distinction between biosimilars and biobetters has important impli-
cations from a regulatory perspective, with biosimilars following class-specific 
guidance whereas biobetters are considered innovator drugs. This study sought 
to examine and compare the regulatory and reimbursement approaches to the 
appraisal of biobetters and biosimilars. MethOds: Biobetters and biosimilars of 
the same product class were identified, and qualitative analyses of the recommen-
dations by indication, evidence considered, and key decision drivers were under-
taken using available regulatory and HTA reimbursement decision documentation 
from six European countries. Results: Findings for filgrastim are presented as 
an example; 7 biosimilars, and the pegylated filgrastims (pegfilgrastim and lipegfil-
grastim) considered biobetters, were identified. Biosimilar filgrastims were granted 
European marketing authorisation based on demonstration of clinical comparabil-
ity to the originator filgrastim in one indication and extrapolation of the results 
to all 5 approved indications. Pegfilgrastim demonstrated clinical non-inferiority 
to filgrastim in one indication and was approved solely for this indication; the 
subsequently developed lipegfilgrastim was approved for the same indication but 
used pegfilgrastim as the comparator. Similar to biosimilar filgrastims, economic 
evidence in the form of cost-minimisation analyses was considered in HTA recom-
mendations of both pegylated filgrastims. This differs from the approach for certain 
other biobetters that have demonstrated clinical superiority and cost-effectiveness 
versus their originator. cOnclusiOns: Biosimilars and biobetters are subject to 
distinct regulatory processes and the decision driving factors for reimbursement 
also differ among currently licensed biobetters. With the development of these 
products gaining momentum, it will be interesting to observe how the appraisal 
processes evolve to address the scope and variety of emerging biobetters.
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Objectives: In Germany, with the introduction of the Pharmaceutical Market 
Restructuring Act (AMNOG) in January 1st2011, pricing and reimbursement deci-
sions for new drugs have been driven by the early benefit assessment (EBA). G-BA 
can decide to set or not a time limitation to the decision. The objectives of this 
study were, first, to review the number of time-limited decisions over time and 
second, to identify drivers of these decisions. MethOds: G-BA’s decisions, from the 
introduction of AMNOG Law to June 1st2014, were reviewed. Exempted and/or 
cancelled procedures were excluded. Results: As of June 1st 2014, 76 EBAs were 
concluded and time limits, from 1 to 5 years, were imposed on 28% (21/76) of these 
decisions. Short-term restrictions (≤ 2 years) accounted for 52% (11/21) of the time-
limited decisions and long-term (> 2 years) for 48% (10/21). Time-limited decisions 
concerned largely oncology drugs (62%; 13/21), followed by endocrine/metabolic 
drugs (19%; 4/21) and neurology drugs (10%; 2/21). The number of time limited deci-
sions increased over the studied period, from none (0/2) of the decisions in 2011 to 
16% (3/19) in H1 2012, 38% (3/8) in H2 2012, 20% (3/15) in H1 2013, 35% (7/20) in H2 
2013 and reaching 42% (5/12) from January 1st to June 1st 2014 decisions. Time-limited 
decisions were triggered by one or several factors, with safety concerns being the 
major driver (38%; 8/21). Other drivers were uncertainties of outcomes (33%; 7/21), 
ongoing studies (33%; 7/21), lack of data (24% (5/21), European Medicine Agency’s 
(EMA) conditional approval (19%; 4/21), design uncertainty (10%; 2/21), inappropriate 
comparator (10%; 2/21), quality of life concerns (10%; 2/21), and EMA requirements 
for post-authorisation studies or risk management plan (10%; 2/21). cOnclusiOns: 
An increasing trend for time-limited decisions was observed. Time restricted deci-
sions have become a major uncertainty management tool in Germany.
PHP161
reimbursement trends and evidence reQuirements for ultra-
orPHan tHeraPies across euroPe: oPtimising market access in 
increasingly cHallenging markets
Morawski J.1, Paul A.2, Ransom J.F.3, Spinner D.S.4, Doyle J.J.5, Faulkner E.C.6
1Quintiles, Cambridge, Ma, Usa, 2Quintiles Consulting, Durham, NC, Usa, 3Quintiles Global 
Consulting, Hawthorne, NY, Usa, 4Quintiles, Durham, NC, Usa, 5Quintiles, Hawthorne, NY, Usa, 
6Institute for Pharmacogenomics and Individualized Therapy, eshelman school of Pharmacy, 
University of North Carolina, Chapel Hill, NC, Usa
Objectives: Ultra-orphan diseases are extremely rare conditions many of which 
are severe, chronic, and progressive with high mortality rates. There is a growing 
number of therapies for ultra-rare diseases currently on the market. Reimbursement 
decisions for these therapies have been characterized by reduced evidence require-
ments with unmet need weighing heavily into health technology assessment (HTA) 
and reimbursement decision-making; as well as a generally wide pricing latitude. 
To gain insight into evolving market access requirements, we conducted a review 
of pan-European ultra-orphan therapy HTA requirements and reimbursement deci-
sions. MethOds: Applying the National Institute for Health and Care Excellence 
(NICE) definition for ultra-orphan diseases (prevalence of ≤ 1/50,000), full European 
HTA reports on ultra-orphan therapies published through May 2014 were identified 
and reviewed to compare evidence requirements and reimbursement decisions 
across countries for health economic, clinical, and value based criteria. Results: 
Over sixty published ultra-orphan HTAs were identified across nine markets. A 
small portion of these submissions were rejected for reimbursement largely due 
to lack of evidence on clinical benefit. For therapies recommended with access 
restrictions, payers often requested additional follow-on studies or ongoing moni-
toring of patients by manufacturers. With respect to economic evidence evaluation, 
reimbursement decisions predominately hinged on therapy cost per patient per 
year, rather than cost-effectiveness. More recent assessments also evaluated qual-
ity of life evidence and input from patient groups. cOnclusiOns: As health care 
budgets become more strained, ultra-orphan therapies priced at a premium have 
come under increased scrutiny from HTA agencies and payers to demonstrate value 
for money. In order to achieve optimal market access, manufacturers must consider 
continually evolving stakeholder evidence requirements and develop clinical and 
health economic value plans that demonstrate how their ultra-orphan therapies 
provide health gain instead of disease stabilization.
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Objectives: Ultra-orphan diseases affect a very small patient population, defined 
by the National Institute for Health and Care Excellence (NICE) as those diseases 
with a prevalence of ≤ 1: 50,000. Medicines for these indications are difficult to 
develop in part due to challenges associated with recruiting for clinical trials 
from a small patient population. Within this context, global payer bodies have 
assessed these therapies with modified evidence requirements and opportunity 
for very high prices. We performed a health technology assessment (HTA) review 
of two ultra-orphan products – eculizumab/Soliris and iduronate-2-sulfatase (IDS)/
Elaprase – to gain insight into the evolving HTA evidence requirements for ultra-
orphan medicines and comparatively evaluate key decision drivers across geogra-
phies. MethOds: We scanned global HTAs published before end of May 2014 to 
identify the two most widely assessed ultra-orphan therapies that have variable 
reimbursement decision outcomes (eculizumab/Soliris and IDS/Elaprase). To evalu-
ate pivotal decision drivers, we analyzed HTAs across several criteria, including 
clinical efficacy, unmet need, strength of evidence, cost-effectiveness and burden 
of illness. Results: We identified HTAs in seven countries. For both products, 
reimbursement decisions varied across agencies. Key decision drivers included 
cost-effectiveness, clinical efficacy, risk-sharing schemes, and lowered evidence 
requirements/ special criteria for ultra-orphan medicines. Assessments rejecting 
Soliris and Elaprase (e.g., Australia, Canada, UK) did so based on cost-effectiveness 
and lack of long-term survival data. Notably, the NICE Highly Specialized Technology 
Committee requested unprecedented justification of Soliris pricing. Some agencies 
(e.g, Scottish Medicines Consortium [SMC]) preemptively rejected the products due 
to manufacturer non-submission of required data. In Australia, Soliris gained recom-
mendation alongside a risk-sharing scheme while Elaprase gained recommendation 
under Life Saving Drugs Program criteria. cOnclusiOns: Eculizumab and IDS are 
among a select list of therapies commanding very high prices globally. This study 
demonstrates variability in decision criteria and approaches across HTA agencies 
for such high-priced ultra-orphan products.
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Objectives: Market access for an innovative technology, such as a biologic 
obtaining a license in a second indication, can be complex and time consuming. 
Reimbursement is critical to rapid adoption of and optimal patient access to a new 
technology. This study aimed to determine the best approach for communicating 
value and providing field-based staff with value resources to facilitate dialogue 
with stakeholders in various scenarios. MethOds: We conducted desktop research 
of published literature, health technology assessment reports, clinical trials data, 
and third-party websites to identify the critical path and data most valuable to 
reimbursement decision making in order to prepare a communication resource. 
We conducted a country-affiliate workshop and qualitative one-on-one interviews 
with payer decision makers in several key markets to understand funding flow and 
the most appropriate means of communicating value to external decision mak-
ers. Results: The process and restrictions for biologics may be stricter than for 
other medications because of perceived high cost. There are multiple appropriate 
access pathways for various settings of care, all with varying requirements and 
value drivers. It is critical to understand the needs of external decision makers 
and provide field-based staff with a consistent yet customizable means of com-
municating the value of new technologies. All evidence and insights were synthe-
sized into an evidence-based market access value resource for key stakeholder 
